Yazar "Erdogan, Haluk" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Alanya’da yatarak tedavi gören COVID-19 hastalarının geriye dönük analizi(2023) Erdogan, Haluk; Erdogan, AskinAmaç: SARS-CoV-2 virüsünün etkeni olduğu COVID-19 pandemisi dünya genelinde ciddi morbidite ve mortaliteye neden olmaktadır. Bu çalışmada Alanya Alaaddin Keykubat Üniversitesi Alanya Eğitim ve Araştırma Hastanesi’de yatarak takip ettiğimiz kesin tanı almış ilk 50 COVID-19 hastası geriye dönük irdelendi. Yöntemler: Hastanemizde Mart 2020-Mayıs 2021 tarihleri arasında COVID-19 tanısı ile yatırılarak takip ettiğimiz hastalar retrospektif olarak tarandı. Gerçek-zamanlı polimeraz zincir reaksiyonu (RT-PCR) ile SARS CoV-2 viral nükleik asit testi pozitif olan hastalar çalışmaya dahil edildi. Hastane bilgi yönetim sistemi üzerinden hastaların kayıtları ve dosyaları retrospektif olarak tarandı. Hastalığın ciddiyeti hafif, orta, ciddi ve kritik olarak sınıflandırıldı. Demografik, klinik ve laboratuvar verileri hazırlanan formlara işlendi. Bulgular: Onaltı hafif/orta, 34 ciddi/kritik hasta çalışmaya dahil edildi. Hastaların ortalama yaşı 58±15,9 yıl olup %64’ü erkek idi. Hipertansiyon (%28) ve Diabetes mellitus (DM) (%28) en sık saptanan komorbid hastalıklardı. Ciddi ve kritik hastalarda ileri yaş, DM, solunum sıkıntısı, derin lenfopeni (<800), d-dimer yüksekliği, C-reaktif protein (CRP) normal sınırın >20 kat yüksekliği, prokalsitonin yüksekliği (>0.25ng/ml) istatiksel olarak (p<0.05) anlamlı bulundu. Hastaların %92'ne favipiravir verildi. Onsekizi deksametazon (6 mg/gün, 5-10 gün), 3’ü IL-6 reseptör blokeri ve 2’si immün plazma tedavisi aldı. Hafif vakalar dışında tüm hastalara proflaktik veya tedavi dozunda düşük molekül ağırlıklı heparin başlandı. Beş (%10) olguda mortalite gelişti. Mortalite gelişen olguların hepsi erkek, 50 yaş üzerinde olup en az bir komorbidetesi vardı. Sonuçlar: Ciddi ve kritik seyreden olgularda ileri yaş, DM, derin lenfopeni, d-dimer yüksekliği, CRP’nin normal sınırın 20 kat üzerinde olması ve prokalsitonin yüksekliği anlamlı bulundu. COVID-19 hastalarında antiibiyotik tedavisinin düzenlenmesinde prokalsitonin önemli bir biyobelirteçtir.Öğe Effect of serum adropin levels on circulating endothelial dysfunction biomarkers in COVID-19 patients(2023) Gunesacar, Ramazan; Eksi, Durkadin Demir; Alpay, Ali Seydi; Hanikoglu, Ferhat; Erdogan, HalukPurpose: Several studies show that the symptoms of severe COVID-19 infection reflect the clinical phenotype of endothelial dysfunction and share common pathophysiological mechanisms with endothelial dysfunction. Therefore, the aim of the study was to investigate the effect of serum adropin levels on endothelial dysfunction biomarkers and determine whether adropin could be a new biomarker for COVID-19. Materials and Methods: The study included 40 patients with mild/moderate COVID-19, 48 patients with severe/critical COVID-19, and 37 controls. Serum adropin and circulating biomarkers of endothelial dysfunction including asymmetric dimethylarginine (ADMA), endothelin-1 (ET-1), endothelial nitric oxide synthase (eNOS), soluble intercellular adhesion molecule-1 (sICAM-1) and plasminogen activator inhibitor-1 (PAI-1) levels were determined by micro-ELISA. Results: Serum adropin levels were found to be significantly higher in COVID-19 patients (165.2±11.49 pg/ml) than in controls (85.46±12.08 pg/ml). Serum adropin levels of patients with severe/critical symptoms (194±16.23 pg/ml) were significantly higher than the patients with mild/moderate symptoms (130.6 ±14.53). In addition, serum ADMA, eNOS, and, ET-1 levels were significantly higher in the COVID-19 subjects (150.5±8.67 ng/ml, 172.4±14.01 pg/ml, 159.3±10.19 pg/ml, respectively) than that those in the controls (104.5±9.182 ng/ml, 141.4±17.74 pg/ml, 100.1±11.37 pg/ml, respectively). Significant positive correlations were found between adropin and ADMA, eNOS, ET-1, sICAM-1, and PAI-1 levels in the patients. Conclusion: We suggest that adropin may be a new potential biomarker for COVID-19 and an important molecule in restoring endothelial cell damage. Positive correlations between serum adropin levels and ADMA, eNOS, ET-1, sICAM-1 and PAI-1 levels in patients suggest that adropin may compensate for damage to endothelial cells.Öğe Effect of serum adropin levels on circulating endothelial dysfunction biomarkers in COVID-19 patients(Cukurova Univ, Fac Medicine, 2023) Gunesacar, Ramazan; Eksi, Durkadin Demir; Alpay, Ali Seydi; Hanikoglu, Ferhat; Erdogan, HalukPurpose: Several studies show that the symptoms of severe COVID-19 infection reflect the clinical phenotype of endothelial dysfunction and share common pathophysiological mechanisms with endothelial dysfunction. Therefore, the aim of the study was to investigate the effect of serum adropin levels on endothelial dysfunction biomarkers and determine whether adropin could be a new biomarker for COVID-19.Materials and Methods: The study included 40 patients with mild/moderate COVID-19, 48 patients with severe/critical COVID-19, and 37 controls. Serum adropin and circulating biomarkers of endothelial dysfunction including asymmetric dimethylarginine (ADMA), endothelin-1 (ET-1), endothelial nitric oxide synthase (eNOS), soluble intercellular adhesion molecule-1 (sICAM-1) and plasminogen activator inhibitor-1 (PAI-1) levels were determined by micro-ELISA. Results: Serum adropin levels were found to be significantly higher in COVID-19 patients (165.2 & PLUSMN;11.49 pg/ml) than in controls (85.46 & PLUSMN;12.08 pg/ml). Serum adropin levels of patients with severe/critical symptoms (194 & PLUSMN;16.23 pg/ml) were significantly higher than the patients with mild/moderate symptoms (130.6 & PLUSMN;14.53). In addition, serum ADMA, eNOS, and, ET-1 levels were significantly higher in the COVID-19 subjects (150.5 & PLUSMN;8.67 ng/ml, 172.4 & PLUSMN;14.01 pg/ml, 159.3 & PLUSMN;10.19 pg/ml, respectively) than that those in the controls (104.5 & PLUSMN;9.182 ng/ml, 141.4 & PLUSMN;17.74 pg/ml, 100.1 & PLUSMN;11.37 pg/ml, respectively). Significant positive correlations were found between adropin and ADMA, eNOS, ET-1, sICAM-1, and PAI-1 levels in the patients. Conclusion: We suggest that adropin may be a new potential biomarker for COVID-19 and an important molecule in restoring endothelial cell damage. Positive correlations between serum adropin levels and ADMA, eNOS, ET-1, sICAM-1 and PAI-1 levels in patients suggest that adropin may compensate for damage to endothelial cells.Öğe Mediterranean Spotted Fever with Severe Course Detected in Alanya: A Case Report(Doc Design Informatics Co Ltd, 2025) Erdogan, Haluk; Arslan-Akdag, Betul; Guldal, Mustafa; Erdogan, AskinA 40-year-old female patient was admitted to the emergency department with high-grade fever, headache, generalized joint pain, and a history of tick attachment. On physical examination, body temperature was 39.5 degrees C, with diffuse maculopapular rash and conjunctival hyperemia. Laboratory findings include mild anemia, profound lymphopenia, severe thrombocytopenia, severe hyponatremia, markedly elevated procalcitonin and C-reactive protein (CRP) levels, abnormal liver function tests, and severe hypocalcemia. Indirect fluorescent antibody (IFA) testing revealed positivity for both immunoglobulin M (IgM) and immunoglobulin G (IgG) against Rickettsia conorii. The patient responded well to doxycycline therapy and was discharged in good condition. To the best of our knowledge, this is the first reported case of Mediterranean spotted fever identified in the Mediterranean region of T & uuml;rkiye.
